Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of $ !
Request Sample
Diamond Member Since 2024

Suppliers with verified business licenses

Audited Supplier Audited Supplier

Audited by an independent third-party inspection agency

In-stock Capacity
The supplier has In-stock capacity
Fast Delivery
The supplier can deliver the goods within 15 days
OEM Services
The supplier provides OEM services for popular brands
R&D Capabilities
The supplier has 1 R&D engineers, you can check the Audit Report for more information
to see all verified strength labels (13)
  • Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
  • Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
  • Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
  • Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
  • Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
  • Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
Find Similar Products
  • Overview
  • Product Description
Overview

Basic Info.

Certification
GMP, ISO 9001, USP
Suitable for
Adult
State
Powder
Purity
>99%
Sample
Available
OEM
Available
MOQ
1kg
CAS
461432-26-8
Keyword
Dapagliflozin
Keyword 1
Dapagliflozin Powder
Transport Package
1kg Foil Bag /25kg Drum
Specification
99%
Trademark
/
Origin
China
Production Capacity
20000

Product Description

Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin
Product Description

Description

Dapagliflozin is a new type of antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Product name Dapagliflozin
Appearance white Powder
Specification 99%
Shelf life 2 years when properly stored

Function and Application

Dapagliflozin is a drug used to treat type 2 diabetes.It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes.

Dapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material DapagliflozinDapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material DapagliflozinDapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material DapagliflozinDapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material DapagliflozinDapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material DapagliflozinDapagliflozin Powder CAS 461432-26-8 Dapagliflozin Material Dapagliflozin

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier